Works matching IS 03407004 AND DT 2003 AND VI 52 AND IP 3
Results: 8
Analysis of in vitro immunization: generation of cytotoxic T-lymphocytes against allogeneic melanoma cells with tumor lysate-loaded or tumor RNA-transfected antigen-presenting cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 3, p. 171, doi. 10.1007/s00262-002-0339-6
- By:
- Publication type:
- Article
Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 3, p. 185, doi. 10.1007/s00262-002-0357-4
- By:
- Publication type:
- Article
IL-12: a promising adjuvant for cancer vaccination.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 3, p. 133, doi. 10.1007/s00262-002-0356-5
- By:
- Publication type:
- Article
A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 3, p. 155, doi. 10.1007/s00262-002-0360-9
- By:
- Publication type:
- Article
Melphalan-induced up-regulation of B7–1 surface expression on normal splenic B cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 3, p. 162, doi. 10.1007/s00262-002-0345-8
- By:
- Publication type:
- Article
Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 3, p. 145, doi. 10.1007/s00262-002-0340-0
- By:
- Publication type:
- Article
Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 3, p. 194, doi. 10.1007/s00262-002-0355-6
- By:
- Publication type:
- Article
Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 3, p. 179, doi. 10.1007/s00262-002-0369-0
- By:
- Publication type:
- Article